Difference between revisions of "Ferric carboxymaltose (Injectafer)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
m |
||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron. |
| − | + | *2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have non–dialysis-dependent chronic kidney disease. | |
| − | * | ||
==Also known as== | ==Also known as== | ||
Revision as of 16:52, 9 May 2023
General information
Class/mechanism: Colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron.
- 2013-07-25: Approved for the treatment of iron deficiency anemia in adult patients who have non–dialysis-dependent chronic kidney disease.
Also known as
- Brand name: Injectafer